SGLT2 Inhibitor Utilization Re-perfusion Therapy (SUPER)
The Role of SGLT2 Inhibitors in Stroke-reperfusion Injury:A Multi-Center, Randomized, Open-Label, Controlled Trial
Sponsor: Taichung Veterans General Hospital
A PHASE4 clinical study on Acute Ischemic Stroke From Large Vessel Occlusion, this trial is actively recruiting participants. The trial is conducted by Taichung Veterans General Hospital and has accumulated 4 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
4 versions recorded-
Feb 2026 — Present [monthly]
Not Yet Recruiting PHASE4
-
Dec 2025 — Feb 2026 [monthly]
Not Yet Recruiting PHASE4
-
May 2025 — Dec 2025 [monthly]
Not Yet Recruiting PHASE4
-
Apr 2025 — May 2025 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Taichung Veterans General Hospital
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.